Articles published by QIAGEN N.V.
 
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Proposes Expansion of Supervisory Board
    
   May 11, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
    
   May 05, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
    
   
    QIAGEN N.V. to release results for Q1 2022 and hold Webcast
    
   April 20, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Announces 20-F Annual Report Filing for 2021 Results
    
   March 14, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
    
   February 08, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
    
   February 07, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
    
   January 27, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
    
   
    QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
    
   January 19, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
    
   
    QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
    
   January 07, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
    
   January 06, 2022
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
    
   
    QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
    
   December 02, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
    
   
    QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
    
   November 08, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN and BD Settle Patent Infringement Lawsuit
    
   November 05, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
    
   November 02, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
    
   October 19, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
    
   September 30, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
    
   September 03, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
    
   
    QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
    
   August 23, 2021
   From QIAGEN N.V.
   Via Business Wire
    Tickers
      QGEN
    
   
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.